with an increase in the serum triglyceride (TG) levels and a decrease in the high-density lipoprotein (HDL) plasma levels. 6 It has been shown that cardiovascular disorders (CVDs) due to advanced atherosclerosis are one of the major causes of death among patients with renal insufficiency, and dyslipidemia is the most critical risk factor for these events due to vascular calcification and atherosclerotic plaque formation. 7, 8 It is important to note that mortality rate from heart diseases in these patients is 30 times higher than that of healthy subjects. 9 About 40% of patients undergoing hemodialysis suffer from dyslipidemia and prevalence of metabolic syndrome, and hypertension plus dyslipidemia have been reported to be as high as 77% in these patients. 7 Given that there are approximately 35000 dialysis and transplantation patients in Iran, 10 paying attention to the problems of these patients is essential.
L-carnitine is quaternary ammonium found in milk and meat. The liver is also one of the main sources of endogenous carnitine producing it from lysine, methionine, ascorbate, niacin, pyridoxine, and iron. Carnitine is used in a variety of metabolic processes, including the regulation of Ketogenesis as well as mitochondrial processes, and the transfer of free fatty acids. 11 Studies have shown that carnitine supplementation among patients undergoing dialysis decreases inflammatory responses and also improves their metabolic status. 12 Moreover, carnitine has lipid-lowering effects and improves lipid metabolism, and is effective in preventing hypotension during hemodialysis. 13 On the other hand, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) inhibitors, such as atorvastatin, have been long known to possess remarkable lipid-lowering effects. 7 Although both statins and carnitine are effective in reducing the level of plasma lipids, the effects of their combination on the lipid profile of patients undergoing dialysis are unclear. The purpose in this study was to investigate and compare the effect of atorvastatin plus carnitine combination therapy with atorvastatin alone on blood lipid profile of patients undergoing dialysis. All patients who were over 18 years of age and under hemodialysis were included in this study. Moreover, all patients who took any other medication to control his/her lipid profile were excluded from the study. Furthermore, if the patients did not fill in the informed consent form to participate in the study, they would be excluded. 50 patients who were over 18 years old, under hemodialysis and referred to the educational hospitals of TUOMS were enrolled into the study. The patients were randomly selected using convenient sampling method. All patients were randomly assigned to two equal groups (n = 25 each) using a random number table. In both groups, the haemoglobin and level of lipid profiles of patients including total cholesterol, TG, low-density lipoprotein (LDL), and HDL were measured in an academic laboratory at the beginning of the study and six months after treatment. One group of patients (n = 25) were treated with atorvastatin at a 10 to 80 mg daily dose (according to the baseline level of lipid profile in patients). The second group (n = 25) was treated with atorvastatin at a dose of 10 to 80 mg daily and carnitine 1000 mg three times daily with food for six months. The lipid profile of the patients in the first and third months was used to adjust the dosage of atorvastatin, as needed. During the study, all possible side effects of carnitine were also recorded (side effects of carnitine are rare, and in case of some complications, patients would be examined by their physician, who would take necessary measures such as discontinuation of the drug).
For all statistical analyses, the SPSS (version 20, IBM Corporation, Armonk, NY, USA) was used. Data were expressed as mean ± standard deviation (SD), frequency, and percentage. The normal distribution of data was evaluated using KolmogorovSmirnov (K-S) test. Chi-square test was used to compare the qualitative variables. In addition, the quantitative variables were compared between two groups using independent t-test or Mann Whitney U test. The sample size of the study was determined based on the previous studies and online at http://www.parsmodir.com/db/research/c ochran.php website using the Cochran formula. The power of the study (1-β) and α were considered to be 80% and 0.05, respectively. In all comparisons, P < 0.050 was considered as statistically significant.
The purpose and manner of conduction of the study, potential benefits, and potential side effects of carnitine (based on previous studies, the incidence of severe side effects is unlikely) were utterly explained to the patients. It was also stated that all of their information would be kept confidential, and their personal information would not be mentioned anywhere. Informed written consent of the patients was also obtained from the patients.
Throughout the study, except for the administration of atorvastatin alone or atorvastatin with carnitine, no additional intervention was performed on the patients. In addition, the cost of the drugs used in the study and the relevant tests was provided by the project implementer and supported by the vice chancellor of TUOMS, and no additional charges were received from patients and their families.
General study characteristics:
In the atorvastatin group, 10 (40.0%) and 15 (60.0%) of the patients were men and women, respectively. Moreover, in the atorvastatin plus carnitine group, 15 (60.0%) and 10 (40.0%) of the patients were men and women, respectively. There was no significant difference regarding gender between the two groups (P = 0.258).
The mean age of the patients was 50.08 ± 12.90 and 47.12 ± 13.18 years in the atorvastatin group and in the atorvastatin plus carnitine group, respectively. The two groups did not have a significant difference in terms of their mean age (P = 0.426).
Lipid profile of the patients: The mean of TG level in the two groups was not significantly different at the beginning of the study (P = 0.780). After intervention for six months, the level of TG in the atorvastatin plus carnitine group was considerably lower than that of atorvastatin group (P = 0.002) (Figure 1) . Furthermore, the mean total cholesterol level in the two groups was not significantly different at the beginning of the study (P = 0.371). However, after treatment, total cholesterol level was significantly lower in the atorvastatin plus carnitine group compared to that of the atorvastatin group (P = 0.024) (Figure 2 ).
In addition, the mean LDL and HDL levels in the two groups were not significantly different at the beginning of the study (P = 0.183 and P = 0.296, respectively). On the other hand, after intervention, the LDL and HDL levels were significantly lower in the atorvastatin plus carnitine-treated group in comparison to the other one (P = 0.001 and P = 0.001, respectively) ( Figures 3 and 4) . Moreover, the mean of haemoglobin level in the two study groups was not significantly different at the beginning of the study (P = 0.765). However, after intervention for six months, haemoglobin levels were significantly higher in the atorvastatin plus carnitine group compared to the atorvastatin alone group (P = 0.032). During the study, no significant side effect of carnitine or atorvastatin was reported (Table 1 ).
Figure 4. Comparison of high-density lipoprotein (HDL) level of patients before and after intervention
The Global Burden of Disease Study (GBD) stated renal failure as one of the three leading causes of death in the world. 14 Mortality in patients with CKD is associated with a combination of socioeconomic causes, related illnesses, modalities for renal replacement therapy, and kidney failure itself. Furthermore, CVDs are more common than the general population and are a common cause of death in these patients. CKD causes the impairment of production of many major enzymes and receptors involved in the metabolism of lipoproteins, especially HDL which leads to dyslipidemia in these patients. Reduced activity of lipoprotein lipase or hepatic TG lipase has also been reported in CKD patients increasing plasma TG level. 15, 16 Moreover, carnitine deficiency, which is commonly found in hemodialysis patients, is an important contributing factor to uremic hyperlipidemia. 17 Carnitine is a natural substance with the main physiological role to transfer long-chain fatty acids from the cytoplasm in order to the mitochondria for their beta-oxidation. Therefore, the presence of sufficient amounts of carnitine in the cells is essential for the normal metabolism of fatty acids in the human body. 18 In this study, it was shown that administration of atorvastatin plus carnitine for six months significantly lowered the TG, cholesterol, and LDL levels compared to atorvastatin alone. In addition, treatment with this combination increases the level of HDL and haemoglobin among patients with CKD which is remarkably higher than that of atorvastatin alone.
Similarly, in a study by Fukami et al. 19 it was revealed that intravenous administration of carnitine for 1 to 4 weeks decreased serum free fatty acids and increased HDL. The results of this study were consistent with the those of the current study.
In another study, Wanner et al. examined the effect of atorvastatin (20 mg/day) on 1255 hemodialysis patients with type 2 diabetes mellitus (DM) and compared it with placebo. The results of this study showed that after four weeks of treatment, LDL levels decreased by 42% in patients receiving atorvastatin, compared to a 1.3% decrease in the placebo group. 20 However, in the present study, the effects of simultaneous administration of atorvastatin and carnitine were compared with those of atorvastatin alone. Accordingly, after six months of receiving the relevant treatments, the lipid profile and haemoglobin profile of the patients in the carnitine-recipient group were significantly better than the other group.
In a study, Chen et al. reviewed the effect of carnitine on the lipid profile in patients with renal failure. In this study, 49 clinical trials with 1734 patients were studied. The results of this study showed that carnitine significantly decreased the level of LDL, with no change in the level of TG, HDL, haemoglobin, and hematocrit (HCT) among patients with CKD. Moreover, no side effects were reported with L-carnitine use. 21 On the other hand, Makhlogh et al. conducted a study to investigate the effect of carnitine on the lipid profile of hemodialysis patients suffering from heart disease. However, the results of this study showed that administration of carnitine for three months did not affect serum lipid levels in hemodialysis patients. 22 Furthermore, in another study by Ahmadi et al., it was showed that supplementation with carnitine (1 g/day) for three months did not change the mean TG as well as total cholesterol levels and serum total antioxidant capacity compared to the control group. However, it significantly reduced LDL cholesterol compared to the other group. 23 In conclusion, based on the results of this study and most studies in this field, the use of carnitine is an effective and safe method for treatment of dyslipidemia and also improvement of anaemia in hemodialysis patients. Moreover, its use in combination with atorvastatin is an appropriate strategy for management of dyslipidemia among patients with CKD. Some of the discrepancies observed in this regard are due to differences in sample selection and study method, duration of treatment, as well as the variables studied. Due to the lack of definitive findings in medical reference books, further studies in this field is necessary for better decision making.
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